Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMO | Q99835 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333239 | 0.89 | NPC1 (0.66) | SMN1; SMN2KDM4EALDH1A1RAB9ANPC1 | |
| SCHEMBL14134365 | 0.89 | NPC1 (0.51) | SMN1; SMN2CLK1GAAKDM4EALDH1A1 | |
| SCHEMBL12343770 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2CLK1GAAKDM4EALDH1A1 | |
| SCHEMBL14134378 | 0.79 | NPC1 (0.64) | GAAKDM4EALDH1A1RAB9ANPC1 | |
| SCHEMBL3331931 | 0.78 | SMN1; SMN2 (0.82) | SMN1; SMN2CLK1GAAKDM4EALDH1A1 | |
| SCHEMBL10389628 | 0.77 | BRAF (0.55) | SMN1; SMN2GAAKDM4EALDH1A1RAB9A | |
| SCHEMBL12344016 | 0.77 | NPC1 (0.67) | SMN1; SMN2CLK1KDM4EALDH1A1HTT | |
| SCHEMBL2624788 | 0.76 | ABCB1 (0.71) | SMN1; SMN2CLK1GAAKDM4EALDH1A1 | |
| SCHEMBL3333917 | 0.76 | SMN1; SMN2 (0.58) | SMN1; SMN2CLK1GAAKDM4EALDH1A1 | |
| SCHEMBL14139837 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2CLK1GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471529-A2 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | Emory University (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2364702-A2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | Emory University (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | SMN1; SMN2 4310/4885CLK1 252/4885GAA 2254/4885 |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, HGFAC | SMN1; SMN2 4353/4885CLK1 2511/4885GAA 2319/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | SMN1; SMN2 4310/4885CLK1 252/4885GAA 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.